4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $300,467 | $792,775 | $718,521 | $608,405 |
| - Cash | $149,336 | $249,108 | $218,642 | $153,001 |
| + Debt | $24,606 | $14,671 | $16,124 | $16,448 |
| Enterprise Value | $175,737 | $558,338 | $516,003 | $471,852 |
| Revenue | $37 | $20,723 | $3,129 | $18,038 |
| % Growth | -99.8% | 562.3% | -82.7% | – |
| Gross Profit | $37 | -$76,373 | -$77,124 | -$43,322 |
| % Margin | 100% | -368.5% | -2,464.8% | -240.2% |
| EBITDA | -$181,136 | -$108,663 | -$107,629 | -$69,810 |
| % Margin | -489,556.8% | -524.4% | -3,439.7% | -387% |
| Net Income | -$160,868 | -$100,837 | -$107,494 | -$71,317 |
| % Margin | -434,778.4% | -486.6% | -3,435.4% | -395.4% |
| EPS Diluted | -2.98 | -2.58 | -3.12 | -2.46 |
| % Growth | -15.5% | 17.3% | -26.8% | – |
| Operating Cash Flow | -$134,585 | -$75,792 | -$86,685 | -$69,134 |
| Capital Expenditures | -$3,786 | -$2,771 | -$11,536 | -$9,110 |
| Free Cash Flow | -$138,371 | -$78,563 | -$98,221 | -$78,244 |